Search - tctmd.com

Displaying 1 - 20 of 48

Sort: Relevancy | Date

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

Societies Update Appropriate Use Criteria for Cardiac Implantable Devices

Todd Neale

January 23, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

L.A. McKeown

December 05, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2024

Shelley Wood

April 30, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Caitlin E. Cox

August 30, 2023

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Daily News

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

Shelley Wood

May 09, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Daily News

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

L.A. McKeown

March 27, 2023

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

Todd Neale

March 15, 2023

Advertisement

What’s Going to Be Hot at ESC Congress 2025?

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

What’s Going to Be Hot at ACC 2025?

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Societies Update Appropriate Use Criteria for Cardiac Implantable Devices

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

August 2024 Dispatch for the CV Team

TCTMD’s Top 10 Most Popular Stories for April 2024

What’s Going to Be Hot at ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Debating the Role of T-TEER in the Sickest Patients

What’s Going to Be Hot at AHA 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content